PT30

PT30 is a preclinical-stage, small molecule intravenous (IV) iron therapy being developed by Shield Therapeutics for the treatment of iron deficiency. It is specifically designed as a hypo-allergenic formulation to minimize the risk of hypersensitivity and allergic reactions often associated with existing IV iron treatments. As an advanced iron formulation, it aims to provide a safer alternative for patients who require rapid iron replenishment but are at risk of adverse immune responses. The drug is part of Shield Therapeutics' broader pipeline of iron-based therapies, which includes both oral and intravenous candidates.